Please assess the completion status of the following clinical trial:

Trial Title: Procollagen-3 Driven Corticosteroids for Persistent Acute Respiratory Distress Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>= 18 years~* Continuous endotracheal ventilation~* Moderate - severe ARDS according to Berlin definition with PaO2/FiO2 ≤ 200 with PEEP \>= 5 cm H2O~* Date of ARDS onset : \>= day 5 and ≤ day 14 after the onset of ARDS criteria (regardless of ARDS severity)~* Procollagen III above 9 µg/L in a bronchoalveolar lavage performed by the attending physician between day 3 and day 13 after the onset of ARDS and realized within 5 days prior to randomization~Exclusion Criteria:~* Known pregnancy or breast feeding~* Participation to another interventional trial within 30 days with mortality or ventilator free days as the main endpoint~* Clinical evidence of active untreated infection~* A known, undrained abscess~* Intravascular nidus of infection~* Disseminated fungal infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Methylprednisolone Group (Type: EXPERIMENTAL): Ventilated patients presenting moderate to severe ARDS with a procollagen III alveolar level above 9 µg/L will receive methylprednisolone
- Control Group (Type: PLACEBO_COMPARATOR): Ventilated patients presenting moderate to severe ARDS with a procollagen III alveolar level above 9 µg/L will receive placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).